Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine

Clinical and Vaccine Immunology

Volumn 19, Issue 5, 2012, Pages 659-665

  Moran, Elizabeth E ^a   Burden, Robert ^a   Labrie III, Joseph E ^a   Wen, Zhiyun ^b   Wang, Xin Min ^b   Zollinger, Wendell D ^a   Zhang, Lan ^b   Pinto, Valerian B ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL ANTIGEN; BACTERIAL VACCINE; FHBP ANTIGEN; LIPOOLIGOSACCHARIDE ANTIBODY; NADA ANTIBODY; NEISSERIA MENINGITIDIS VESICLE VACCINE; OPCA ANTIGEN; PORA ANTIBODY; PORIN A; TRIPLE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; MEMBRANE VESICLE; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SEROTYPE;

ADHESINS, BACTERIAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; FEMALE; LIPOPOLYSACCHARIDES; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PORINS; RABBITS; SECRETORY VESICLES;

EID: 84860330309     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00070-12     Document Type: Article

References (34)

1. Armand J, Arminjon F, Mynard MC, Lafaix C. 1982. Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: Clinical and serological evaluation. J. Biol. Stand. 10:335-339. (Pubitemid 13186422)
2. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM. 2009. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J. Infect. Dis. 199:1361-1368.
3. Boisier P, et al. 2007. Meningococcal meningitis: Unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin. Infect. Dis. 44:657-663.
4. Bonvehi P, et al. 2010. Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults. Clin. Vaccine Immunol. 17:1460-1466.
5. Bröker M, Dull PM, Rappuoli R, Costantino P. 2009. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine 27:5574-5580.
6. Claassen I, et al. 1996. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14:1001-1008. (Pubitemid 26271074)
7. Comanducci M, et al. 2002. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195:1445-1454. (Pubitemid 34602821)
8. Delrieu I, et al. 2011. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PloS One 6:1-8.
9. Findlow J, et al. 2010. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51:1127-1137.
10. Finne J, Leinonen M, Makela PH. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet ii:355-357. (Pubitemid 13028927)
11. Fisseha M, et al. 2005. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect. Immun. 73:4070-4080. (Pubitemid 40923147)
12. Giuliani MM, et al. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103:10834-10839. (Pubitemid 44148381)
13. Gotschlich EC, Liu TY, Artenstein MS. 1969. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J. Exp. Med. 129:1349-1365.
14. Keiser et al. 2011. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29:1413-1420.
15. Koeberling O, Delany I, Granoff DM. 2011. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicles vaccines. Clin. Vaccine Immunol. 18:736-742.
16. Maiden MC, et al. 1998. Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl. Acad. Sci. U. S. A. 95:3140-3145. (Pubitemid 28135868)
17. Martin P, Makepeace K, Hill SA, Hood DW, Moxon ER. 2005. Microsatellite instability regulates transcription factor binding and gene expression. Proc. Natl. Acad. Sci. U. S. A. 102:3800-3804. (Pubitemid 40354692)
18. Masignani V, et al. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789-799. (Pubitemid 36350873)
19. Moran EE, Brandt BL, Zollinger WD. 1994. Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity. Infect. Immun. 62:5290-5295. (Pubitemid 24364966)
20. Mothibeli KM, et al. 2011. Distribution of factor H binding protein beyond serogroup B: Variation among five serogroups of invasive Neisseria meningitidis in South Africa. Vaccine 29:2187-2192.
21. Mueller JE, et al. 2007. Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003. Emerg. Infect. Dis. 13:847-854. (Pubitemid 46890132)
22. Mutonga DM, et al. 2009. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006. Am. J. Trop. Med. Hyg. 80:619-624.
23. National Research Council. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
24. Norheim G, et al. 2006. Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989. J. Clin. Microbiol. 44:861-871.
25. Norheim G, et al. 2008. Specificity of the sub-capsular antibody responses following serogroup A meningococcal disease in Ethiopian patients. Clin. Vaccine Immunol. 15:863-871. (Pubitemid 351967033)
26. Pillai S, et al. 2005. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 23:2206-2209. (Pubitemid 40341452)
27. Pinto VB, et al. 2011. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine 29:7752-7758.
28. Reisinger KS, et al. 2009. Quadrivalent meningococcal vaccination of adults: Phase III comparison of an investigational conjugate vaccine, Men-ACWY-CRM, with the licensed vaccine, Menactra. Clin. Vaccine Immunol. 16:1810-1815.
29. Van Den Dobbelsteen G, et al. 2004. From HexaMen to NonaMen: Expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine, p 153. Abstr. 14th Int. Pathogenic Neisseria Conf., Milwaukee WI, 5 to 10 September 2004.
30. Westphal O, Jann K. 1965. Bacterial lipopolysaccharides. Extraction with phenol-water and further application of the procedure. Methods Carbohydr. Chem. 5:83-91.
31. Weynants VE, et al. 2009. Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad crossbactericidal response. Infect. Immun. 77:2084-2093.
32. Zollinger WD, Shoemaker D, Saunders AG, Brandt BL. May 2003. Vaccine against Gram negative bacteria. US patent 6,558,677 B2.
33. Zollinger WD, Moran EE, Schmiel DH. 2009. Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity. Clin. Vaccine Immunol. 16:1789-1795.
34. Zollinger WD, et al. 2010. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 28:5057-5067.